Search Results
Your search for The ASCO Post staff matches 6953 pages
Showing 1 - 50FDA Approves Combination Regimen for Extensive-Stage SCLC
On October 2, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for maintenance treatment of adults with extensive-stage small cell lung cancer (SCLC) whose disease...
Bijal Shah, MD, on CAR T-Cell Therapy in ALL
Bijal Shah, MD, of Moffitt Cancer Center, summarizes his presentation on the role of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), touching on its use in the front-line setting for newly diagnosed patients with high risk-features as well as in patients with...
CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow in the abdomen adjacent to vital organs or enmeshed within the bowel. Given their radioresistant nature, they require high doses of radiation that risk...
Kidney Cancer Cases Expected to Double by 2050
Projected cases of kidney cancer are expected to double by 2050 due to modifiable risk factors, according to findings and estimations published in European Urology. “Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for this steep rise,” stated ...
Impact of Proton and Photon Therapy on HRQOL in Breast Cancer
Health-related quality-of-life measurements demonstrated that both proton and photon radiation therapy led to excellent and similar impacts on quality of life for patients with breast cancer undergoing comprehensive nodal irradiation, according to findings from the phase III RadComp trial that was...
Intermediate-Risk Prostate Cancer: Shorter Radiation Improves Patient Experience, But Not Disease Control
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
SABR May Be Comparable to Surgery for Early-Stage NSCLC
Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...
Patrick Goodley, MBBChir, MRCP: What Is the Optimal Upper Age Limit for Lung Cancer Screening?
Patrick Goodley, MBBChir, MRCP, of Manchester University NHS Foundation Trust, reports results from a study that looked at treatment and survival rates in people aged 75 to 80 years diagnosed with screen-detected lung cancer in two targeted lung cancer screening implementation settings (Abstract...
PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, according to findings from the phase II BALANCE trial (NRG GU006) presented in a press briefing...
Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...
Anthony Letai, MD, PhD, Sworn in as New NCI Director
Anthony Letai, MD, PhD, was sworn in on September 29 as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), by Health and Human Services Secretary Robert F. Kennedy, Jr. Dr. Letai takes the helm of the world’s most prestigious cancer research agency...
Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...
FDA Removes Vandetanib REMS Program
On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency. Vandetanib is a tyrosine kinase inhibitor targeting VEGFR, EGFR, and RET from manufacturer Sanofi (formerly ...
Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International. “This type of cancer, which is a result of...
Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease
The U.S. Food and Drug Administration (FDA) has approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression after at least one line of...
Can Nicotinamide Lessen the Risk of Skin Cancer Development?
The dietary supplement nicotinamide has been recommended by dermatologists for people with a history of skin cancer since 2015, when a clinical study published by Chen et al in The New England Journal of Medicine including almost 400 participants showed that those who took the vitamin B3 derivative ...
Combination Treatment and Patient Selection for Relugolix vs Leuprolide
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses current guideline recommendations for the use of relugolix and leuprolide, relugolix as a combination backbone, and...
Oral vs Injectable Agents for Androgen-Deprivation Therapy in Prostate Cancer
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses forms of hormonal therapy for patients with prostate cancer, with a focus on the HERO trial, which evaluated oral...
More Tattoos, Lessened Risk of Melanoma? New Study Investigates
People with more than one tattoo session may have a decreased risk of developing melanoma—with one key caveat, according to research published by McCarty et al in the Journal of the National Cancer Institute. A team led by Jennifer Doherty, PhD, Huntsman Cancer Institute investigator, Co-Leader of ...
Surgery for Early-Stage Cancer and Opioid Use
Curative-intent surgery for patients with early-stage cancer led to new, persistent, long-term opioid use in more than 1 in 10 opioid-naive veterans, according to the results of an observational study published in Cancer. The results of the study highlighted how necessary it is to develop new pain...
Perioperative Use of Nivolumab With or Without Ipilimumab for Resectable Diffuse Pleural Mesothelioma
Perioperative use of nivolumab with or without ipilimumab may prove to be of benefit for patients with resectable diffuse pleural mesothelioma, according to the findings of a phase II study published in Nature Medicine. Findings from the study were also presented during the International...
James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69
James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical complications from surgery in...
Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertinib—an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR—in patients with HER2-mutant advanced or metastatic non–small cell...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection
The U.S. Food and Drug Administration (FDA) approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda). Efficacy and...
Acute Cystitis May Signal Urogenital Cancer
Acute cystitis signaled the presence of urogenital cancers in middle-aged men and women, according to the results of a Swedish cohort study published in BMJ Public Health. Based on these findings, the researchers suggested that acute cystitis could be used as a clinical marker for urogenital...
City of Hope Awarded $23.7 Million to Map Biomarkers in NSCLC
City of Hope® has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will help City of Hope to create a biomap of tumor changes that cause immunotherapy resistance in advanced ...
New Approvals for Thrombocytopenia, Lung Cancer, Brain Cancer, and Multiple Myeloma
BTK Inhibitor for Chronic Immune Thrombocytopenia: On September 2, 2025, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib (Wayrilz) tablets to treat adults with persistent or chronic immune thrombocytopenia (ITP) who have had an...
Oral Microbiota and Risk for Pancreatic Cancer
Investigators have found several oral bacteria and fungi associated with an increased risk for pancreatic cancer, according to findings published in JAMA Oncology. This cohort study seems to confirm a long-standing suspicion of the relationship between poor oral health and pancreatic cancer and...
David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease
David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the...
Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy
Three leading national cancer organizations have issued an updated guideline on postmastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight...
Policy Review: HRQoL Data in Clinical Trials for Advanced Cancer
A new policy review published by Tannock et al in The Lancet Oncology emphasizes the critical role of health-related quality-of-life (HRQoL) data in the evaluation of treatments for people with advanced cancer. The publication highlights the importance of having standardized responder criteria when ...
Nicholas J. Short, MD: Focus on TP53-Mutated ALL
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur in 10% to 15% of adult patients with ALL. Dr. Short reviews recent research into their impact on...
Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act
Research published by Zheng et al in Health Affairs Scholar found that the passage of the government price-setting provisions of the Inflation Reduction Act (IRA) was associated with a broad decline in industry-funded oncology trials after first U.S. Food and Drug Administration approval, with...
Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML
Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engaged in at the SOHO meeting. They discuss concomitant vs sequential use of lower-intensity regimens in ...
Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer
Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medications that are associated with increased frailty at the time of their cancer diagnosis, according...
New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow
The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...
Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy
Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell...
Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition
Treatment with the viral immunotherapy CAN-2409 helped patients with unresectable, stage III/IV non–small cell lung cancer (NSCLC) continue on immune checkpoint inhibition longer and experience extended survival, despite initial inadequate responses to anti–PD-(L)1 therapy, according to extended...
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...
Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML
Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML).
Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1...
Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib
Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the...
ctDNA May Guide Immunotherapy in Limited-Stage SCLC
A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (Abstract MA11.09) demonstrated that monitoring circulating tumor DNA (ctDNA) may aid in refining and personalizing the use of consolidation immunotherapy in patients with...
Is IFITM3 a Driver of Immunotherapy Response in SCLC?
New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. These findings were presented at the...
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...
Hypofractionated Radiotherapy Plus Concurrent Chemotherapy vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...
